Полиморфизм генов фибриногена у больных с ишемическим инсультом
Диссертация
Молекулярно-генетический анализ однонуклеотидных полиморфизмов С-148Т, 0−455А и С-249Т показывает отсутствие различий в распределении генотипов и частот аллелей между больными с ишемическим инсультом и лицами с хронической сосудистой мозговой недостаточностью. Распределение этих же генотипов, включая полное равновесное сцепление однонуклеотидных полиморфизмов С-148Т и С-455А между собой, и частот… Читать ещё >
Список литературы
- Анисимова A.B. Ранние стадии хронической ишемии головного мозга: Дис.док.мед.наук. Москва, 2004, 248 с.
- Анисимова A.B., Кузин В. М., Колесникова Т. И., Гусев Е. И. Компьютерная морфофункциональная денситометрия эритроцитов в диагностике и прогнозе хронической ишемии головного мозга. Инсульт, 2006- 18- 36−46.
- Боголепов Н.К. Церебральные кризы и инсульт. М.: Медицина, 1972- 392.
- Бочков Н.П. Вклад генетики в медицину. Журнал неврологии и психиатрии имени С. С. Корсакова. 2002- 102 (2): 3−15.
- Верещагин Н.В. Инсульт. Принципы диагностики, лечения и профилактики. М.: Интермедика, 2002- 65.
- Верещагин Н.В. Патология вертебробазнлярной системы и нарушение мозгового кровообращения. М.: Медицина, 1980- 310.
- Вихерт A.M., Жданов B.C. Атеросклероз при различных заболеваниях. М: Медицина 1976- 154 с.
- Гусев Е.И. Ишемическая болезнь головного мозга. М: Медицина, 1992- 14 с.
- Гусев Е.И., Бурд Г. С., Боголепов Н.Н Сосудистые заболевания головного мозга. М.: Медицина, 1979- 142 с.
- Гусев Е.И., Скворцова В. И. Ишемия головного мозга. М: Медицина, 2001- 267 с.
- Давиденкова Е. Ф., Колосова Н. Н., Либерман И. С. Медико-генетическое консультирование в системе профилактики ишемической болезни сердца и инсультов. JI. Медицина, 1979, 194 с.
- Мартынов М.Ю. Ишемический инсульт и хроническая сосудистая мозговая недостаточность. Дис.док. мед. наук. Москва, 2000, 296 с.
- Панченко Е.П., Добровольский А. Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. М: Спорт и культура, 1999- 55−59.
- Селезнев С.А., Назаренко Г. И., Зайцев В. С. Клинические аспекты микрогемоциркуляции. Л. Медицина, 1985- 207 с.
- Скворцова В.И., Лимборская С. А., Кольцова Е. А., Сломинский П. А. Генетика ишемического инсульта. Журнал неврологии и психиатрии им С. С. Корсакова. 2001- 101: приложение «Инсульт» № 4: 15−29
- Суслина З.А., Танашян М. М. Антитромботическая терапия в ангио-неврологии. М: Медицинская книга, 2004- 75 с.
- Танашян М.М. Ишемические инсульты и основные характеристики гемореологии, гемостаза и фибринолиза. Дис.док. мед. наук. Москва, 1997, 281 с.
- Хоанг В. Реологические свойства крови при ишемических нарушениях мозгового кровообращения у больных с атеросклерозом: Дис.канд. мед. наук. Москва, 1992, 162 с.
- Чуканова Е.И. Реологические и свертывающие свойства крови у больных с ишемическим инсультом мозга при лечении антикоагулянтными препаратами. Дис.канд. мед. наук. Москва, 1982, 149 с.
- Шмидт Е.В., Смирнов В. Е. Вопросы эпидемиологии сосудистых заболеваний головного мозга. М: Медицина, 1972, 579 с.
- Ясаманова А.Н. Гемостаз и липиды крови при острой и хронической ишемии головного мозга Дис.докт. мед. наук. Москва, 2005, 253 с.
- American Heart Association. Heart and Stroke Facts: 1996 Statistical Supplement. Dallas, Tex: American Heart Association- 1996.
- American Heart Association. Stroke Statistics. Dallas, Tex: American Heart Association- 2000. Heart and Stroke A Z Guide/strokes.html. Accessed September 2000.
- Asplund K. European White Book on Stroke. 1998.
- Baillie GM, Sherer JT, Weart CW. Insulin and coronary artery disease: is syndrome X the unifying hypothesis. Ann Pharmacother. 1998- 32: 233—47.
- Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost. 1992- 68: 261−3.
- Behar S. Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention. Blood Coagul Fibrinolysis 1999- 10 (Suppl 1): S41−3.
- Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998- 98: 946−52.
- Berndt MC, Ward CM, DeLuca M, et al. The molecular mechanism of platelet adhesion. AustNZ J Med 1995- 25: 822−30.
- Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994- 369: 64.
- Blake GJ, Schmitz C, Lindpaintner K, Ridker PM. Mutation in the promoter region of the 3-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J 2001- 22- 2262−70.
- Blauw GJ, Lagaay AM, Smelt AH, et al. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-Co-A reductase inhibitors. Stroke. 1997- 28: 946−50.
- Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001- 104- 3063−8.
- Bogousslavsky J, Despland P-A, Regli F. Asymptomatic tight stenosis of the internal carotid artery: long-term prognosis. Neurology. 1986- 36: 861—3.
- Born G. Platelets and blood vessels. J. Cardiovasc. Pharmacol. 1984- 4: 706−13.
- Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990- 22: 1505−11.
- Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke 1992- 23- 221−3
- Brass LM, Page WF, Lichtman JH. Stroke in twins III: a follow-up study. Stroke 1998- 29- 256−8.
- Brass LM, Shaker LA. Family history in patients with transient ischemic attacks. Stroke 1991- 22- 837−41.
- Brown ET, Fuller GM. Detection of a complex that associates with the p-fibrinogen G-455-A polymorphism. Blood. 1998- 92- 3286−93.
- Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996- 27: 373−80.
- Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995- 92: 2419 -25.
- Carroll S, Cooke CB, Butterly RJ. Plasma viscosity, fibrinogen and the metabolic syndrome: effect of obesity and cardiorespiratory fitness. Blood Coagul Fibrinolysis 2000- 11: 71−8.
- Carter AM, Catto AJ, Bamford JM. Grant PJ. Gender-spccific association of the fibrinogen Bb 448? Fibrinogen levels and coronary disease. Atherioscler Tromb Vase Biol. 1997- 17: 589−93.
- Carter AM, Catto AJ, Grant PJ. Association of the p-fibrinogen Thr312Ala polymorphism with post stroke mortality in subjects with atrial fibrillation. Circulation. 1999- 99- 2423−6.
- Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. N Engl J Med. 1986- 315: 860−5
- Chen X, Xu M, Zhou W., Chun-li H, Chen W. A meta-analysis of relationship between p-fibrinogen gene -148C/T polymorphism and susceptibility to cerebral infarction in Han Chinese. Chinese Medical Journal. 2007- 120 (13): 1198- 202.
- Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991, 18, 349−55.
- Cook DG, Cappuccio FP, Atkinson RW, Wicks PD, Chitolie A, Nakandakare ER, Sagnella GA, Humphries SE. Ethnic differences in fibrinogen levels: the role of environmental factors and the beta-fibrinogen gene. Am J Epidemiol. 2001- 153 (8): 799−806.
- Cruickshank JM, Neil-Dwyer G, Dorrance DE, et al. Acute effects of smoking on blood pressure and cerebral blood flow. J Hum Hypertens.1989, 3, 443−9.
- Curran JM, Evans A, Arveiler D, Luc G, Ruidavets JB, Humphries SE, Green FR. The ?-fibrinogen T/A312 polymorphism in the ECTIMstudy. Thromb Haemost. 1998- 79: 1057−8.
- Dang C.V., Bell W.R., Shuman M. The normal and morbid biology of fibrinogen. Am. J. med., 1989, 87: 124−37.
- Diaz J.F., Hachinski V.C., Pederson L.L. Aggregation of multiple risk factors for stroke in siblings of patients with brain infarction and transient ischemic attack. Stroke. 1986- 77- 1239−42.
- Dintenfass L. Blood viscosity. MTP Press. Lancaster, 1985.
- Dormandy J. Haemorheological aspects of thrombosis. Brit. J. I laemotol. 1980:45: 519−22.
- Dotevall A, Kutti J, Teger-Nilsson AC, Wadenvik H, Wilhelmsen L. Platelet reactivity, fibrinogen and smoking. Eur J Haematol 1987- 38: 55−9.
- Dougherty J., Levi D., Weksler B. Platelet aggregation in acute cerebral ischemia serial measurements of platelet function in cerebrovascular disease. Lancet 1977- I: 821−4.
- Dyken M. Transien ischemic attacks and aspirin, stroke and death- negative studies and type II error, editorial. Stroke. 1983- 14: 2−4.
- Eliasson M, Asplund K, Evrin PE, Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995- 113: 41−53.
- Elkind M.S., Coates K, Tai W, Paik MS, Boden-Albala B. Levels of acute phase proteins remain sttable after ischemic stroke. Abstract, 2006.
- Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta. 2003- 330- 31—55.
- Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992: 327: 1406−12.
- Fine-Edelstein JS, Wolf PA, O’Leary DH, et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology. 1994- 44: 1046—50.
- Fisher SD, Zareba W, Moss AJ, Marder VJ, Sparks CE, Llochman J, Liang C, Krone RJ. Effect of smoking on lipid and thrombogenic factors two months after acute MI. Am J Cardiol 2000- 86: 813−8.
- Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998- 102- 1369−76.
- Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost. 2001- 86- 366−73.
- Fu Y, Sreekumaran Nair K. Age effect on fibrinogen and albumin synthesis in humans. Am J Physiol 1998- 275 (6 Pt 1): E1023−30.
- Fu Y, Wei X, Ni PH, Ying YY, Song YY, Chen SD. The relationship between the five beta-fibrinogen gene polymorphisms and cerebral infarction. Zhonghua Nei Ke Za Zhi, 2005, 44 (12): 914−7.
- Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992- 326- 242−50.
- Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990- 82(suppl II): 1147−59.
- Gao X, Yang H, ZhiPing T. Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. Neurosci Lett. 2006- 398 (3): 172−7.
- Garvey WT, Hermayer KL. Clinical implications of the insulin resistance syndrome. Clin Cornerstone. 1998- 1: 13−28.
- Giannopoulos S, Kosmidou M, Hatzitolios AI, Savopoulos CG, Ziakas A. Measurements of endotelin-1, C-reactive protein and fibrinogen plasma levels in patients with acute ischemic stroke. Abstract, 2008.
- Gill JS, Shipley MJ, Tsementzis SA, et al. Alcohol consumption: a risk factor for hemorrhagic and non-hemorrhagic stroke. Am J Med. 1991- 90: 489−97.
- Gorelick PB, Rodin MB, Langenberg P, et al. Is acute alcohol ingestion a risk factor for ischemic stroke? Results of a controlled study in middle-aged and elderly stroke patients at three urban medical centers. Stroke. 1987- 18: 359−64.
- Gorelick PB. Cerebrovascular disease in African Americans. Stroke. 1998- 29: 2656−64.
- Gorelick PB. The status of alcohol as a risk factor for stroke. Stroke. 1989- 20: 1607−10.
- Green F., Humphries S. Control of plasma fibrinogen level. Baillieres Clin Hematol. 1989- 2- 945−59.
- Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981- 68: 1370.
- Gueuffier F., Boutitie F., Boissel J.P. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a metaanalysis of individual patient data from randomized, controlled trials. Ann. Intern. Med. 1997- 126: 761−7.
- Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999- 41- 323−33.
- Hanna J.P., Furlan. A. J Cardiac disease and embolic sources. Brain ischemia: Basic concept and clinical relevance. Ed. L.R. Calpan. — London. Springer-Verlag. 1995: 299−315.
- Harland A., Chimowitz MI., Hill HA. Cryptogenic Stroke in Relation to Genetic Variation in Clotting Factors and Other Genetic Polymorphisms Among Young Men and Women Stroke. 2002- 33: 2762−9.
- Hartmann A. Regional cerebral blood flow in acute cerebral infarction during hypervolemic haemodilution. Cerebral vascular disease. 1985.
- Hassan A., Hugh S. Markus. Genetics and ischaemic stroke. Brain 2000- 123: 1784−96.
- Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997- 278:313−21.
- Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronaiy risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994- 14- 54−9.
- Heinrich J, Funke IT, Rust S, Schulte H, Schonfeld R, Kohler E, Assmann G. Impact of polymorphisms in the a- and ?-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients. Thromb Res. 1995- 77: 209−15.
- Hillbom M, Kaste M. Does ethanol intoxication promote brain infarction in young adults? Lancet. 1978- 2: 1181−3.
- Howard G, Evans GW, Toole JF, Tell G, Rose LA, Espeland M, et al. Characteristics of stroke victims associated with early cardiovascular mortality in their children. J Clin Epidemiol 1990- 43- 49−54.
- Hrubec Z, Robinette CD. The study of human twins in medical research. N Engl J Med 1984- 310- 435−41.
- Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD, for the MRF1T Research Group. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor interventional trial. N Engl J Med. 1989- 320: 904−10.
- Iso H, Shimamoto T, Sato S, Koike K, Iida M, Komachi Y. Passive smoking and plasma fibrinogen concentrations. Am J Epidemiol 1996- 144: 1151−4.
- Jates P.O. A change in the pattern of cerebrovascular disease. Lancet 1964- 1- 65−9.
- Johson D.H., Crissman R.S. Endocardial alterations in myocardial infarction. Lab. Invest. 1979: 21−8.
- Joist J.H. Hypercoagulability: Introduction and perspective. Semin. Tromb. Haemostasis, 1990, 16, 151−7.
- Jousilahti P, Rastenyte D, Tuomilehto J, Sarti C, Vartiainen E. Parental history of cardiovascular disease and risk of stroke. A prospective follow-up of 14 371 middle-aged men and women in Finland. Stroke 1997- 28- 1361−6.
- Kannel W., Wolf P. Epidemiology of cerebrovascular disease. Vascular Disease of the Central Nervous System. 1983: 1−24.
- Kannel W.B., Wilson P.R., Bleanger A. J., Gargon D.R. Diabetes, Fibrinogen, and risk of cardiovascular disease. The Framingham experience. Am. Heart J. 1990- 120- 87−94.
- Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979- 241: 2035−8.
- Katsuki S., Hirota Y. Recent trends in incidence of cerebral hemorrhage and infarction in Japan. Jap Heart J 1966- 7- 26−34.
- Khaw KT, Barrett-Connor E. Family history of stroke as an independent predictor of ischemic heart disease in men and stroke in women. Am J Epidemiol 1986- 123- 59−66.
- Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke. The Framingham Study. Stroke 1993- 24- 1366−71.
- Kool MJ, Hoeks AP, Struijker Boudier HA, et al. Short- and long-term effects of smoking on arterial wall properties in habitual smokers. J Am Coll Cardiol. 1993- 22:1881−6.
- Kristensen B, Malm J, Nilsson T, Hultdin J, Carlberg B, Olsson T. Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke. Stroke 1998: 29: 2261−7.
- Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo-Clin Proc. 2000- 75: 369−80.
- Lam KS, Ma OC, Wat NM, Chan LC. G/A-455 polymorphism in relation to fibrinogen concentration and ishaemic heart disease in Chinese patients with type II diabetes. Abstract, 1999.
- Lander ES, Schork N.T. Genetic dissection of complex traits. Science 1994- 265- 2037−48.
- Lee AJ, Lowe GD, Smith WC, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993- 83: 616−21.
- Liao D, Myers R, Hunt S, Shahar E, Paton C, Burke G, et al. Familial history of stroke and stroke risk. The Family Heart Study. Stroke 1997- 28- 1908−12.
- Liu Y, Pan J, Wang S, Li X, Huang Y. (3-Fibrinogen gene 455A/G polymorphism and plasma fibrinogen level in Chinese stroke patients. Chin Med J (Engl). 2002- 115:214−6.
- Loeb C. Transient ischemic attack, protracted transient ischemic attack, and completed stroke. Eur Neurol. 1983- 22: 74−7.
- Majerus PW. Human genetics: bad blood by mutation. Nature. 1994- 369:14.
- Martiskainen M, Pohjasvaara T, Mikkelsson J, Mantyla R, Kunnas T, Laippala P, Ilveskoski E, Kaste M, Karhunen PJ, Erkinjuntti T. Fibrinogen gene promoter 455 A allele as a risk factor for lacunar stroke. Stroke. 2003- 34- 88 691.
- Meade T. W., Haines A. P., North W. R. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentration. Br. Med. J., 1979- 1.
- Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986- 2- 533−37.
- Moller L., Kristensen T. S. Plasma fibrinogen and ischemic heart desease risk factor. Arteriosclerosis. Tromb., 1991- 11- 145−57.
- Ohta K. The clinical importans of haemorheological alteration in cerebrovascular disease. Clinical haemorheology. 1986. 25−32.
- PeerschkeEI. Stabilization of platelet-fibrinogen interactions is anintegral property of the glycoprotein Ilb/IIIa complex. J Lab Clin Med. 1994- 124- 439−46.
- Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989- 1: 175−9.
- Pongracz E, Tordai A, Csomai M, Nagy Z. Genetics of blood coagulation in young stroke patients. Abstract. 2002- 55(3−4): 111−7.
- Powell JT. Vascular damage from smoking: disease mechanisms at the arterial wall. Vase Med 1998- 3: 21 -8.
- Princen U.M.G., Nieuwenhuizen W., Yap S.H. Direct evidence of transcriptional control of fibrinogen and albumin synthesis in rat liver during the acute phase response. Biochem. Biophys. Res. Commun., 1981, 102, 109−16.
- Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997- 277: 739−45.
- Qizilbash N, Jones L, Warlow C, Mann J. fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ. 1991- 303: 605−9.
- Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999- 30: 736−43.
- Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of Hep G2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem. 1990- 265 (11): 6389−93.
- Sacco RL, Boden-Albala B, Gan R, et al. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol. 1998- 147: 259−68.
- Salonen JT, Puska P, Tuomilehto J, Homan K. Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke: a longitudinal study in Eastern Finland. Stroke. 1982- 13: 327−33.
- Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996- 84- 289−97.
- Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension. 2000, 36, 978−91.
- Smith E.B. Fibrinogen, fibrin and the arterial wall. Eur. Heart J., 1995- 16- 24−33.
- Snoweden C, Houlston R, Laker MF. Plasma fibrinogen levels and fibrinogen genotype in non-insulin dependent diabetics. Abstract, 1992.
- Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA. Functional analysis of the fibrinogen Thr312Ala polymorphism: effects on fibrin structure and function. Circulation. 2003- 107- 2326−30.
- Stein P.D., Sabbah H.N. Measured turbulence and its effects on thrombus formation. Circ. Res. 1974- 2: 608−14.
- Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation. 1991- 84: 527−39.
- Voetsch B, Bierl C, Damasceno BP, Annichino-Bizzacchi JM, Arruda VR, Loscalzo J. A novel promoter polymorphism in the plasma glutathione peroxidase gene associated with arterial ischemic stroke in the young. Circulation. 2000- 102:11−704. Abstract.
- Voetsch B., Loscalzo J. Genetic Determinants of ArterialThrombosis. Arterioscler Thromb Vase Biol. 2004- 24: 216−29.
- Wang SJ, Yuan XD, Gao J, Pei HZ, Li HF. Correlation between fibrinogen polymorphisms and the type of cerebral infarction. Abstract. 2005- 22: 572−4.
- Weisel J. W, Stauffacher C. V, Bullitt E., Cohen C.A. A model of fibrinogen: domans andseguence. Science, 1985, 230, 1388−91.
- Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987- 317: 512−26.
- Whisnant JP. Modeling of risk factors for ischemic stroke: the Willis Lecture. Stroke. 1997- 28: 1840−4
- Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984,311, 501−5.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991- 22: 983−8.
- Wolf PA. Cerebrovascular risk. In: Izzo JL Jr, Black HR, Goodfriend TL, et al. Hypertension Primer: The Essentials of High Blood Pressure. Baltimore, Md: Lippincott Williams & Wilkins- 1999, 26, 1120−34.
- Woodward M., Low G. D. O., Rumley A. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. Eur. Heart J., 1998, 19.
- Yatsu F.M., Pettigrew L., Grotta J. Platelet physiology and function: relationship to stroke pathogenesis. Cerebrovascular survey report, NINCD, USA 1985: 209.
- Yu S., Sher B., Kudryk B., Redman C.M. Fibrinogen precursors. Order of assembly of fibrinogen chain. J. Biol. Chem., 1984- 259- 47−59.